No longer trading

Filed for bankruptcy

The bankruptcy filing was reported on August 28, 2026 (SEC 8-K 1.03). Its last closing price was on September 4, 2026. It has left the AI-ranked universe. The score and rank below are its final ones, from August 25, 2026. Source: SEC 8-K 1.03

BTAI

BioXcel Therapeutics, Inc. BTAI

NasdaqSmall CapHealthcare

Final 13F Pro quality score

Final rank #3,030 of 3,053 · as of August 25, 2026

Why it scores 8Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$182.0K

Quarter to Jun 30

Net income

$-14.71M

Quarter to Jun 30

Free cash flow

$-6.10M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$8.69M total
MILLENNIUM MANAGEMENT LLC
$2.98M+9.2%
OAKTREE CAPITAL MANAGEMENT LP
$1.95M+472.3%
VANGUARD CAPITAL MANAGEMENT LLC
$1.30M+343.5%
Oaktree Fund Advisors, LLC
$346.3K+472.3%
GEODE CAPITAL MANAGEMENT, LLC
$341.9K+5.2%
BlackRock, Inc.
$253.0K+112.9%
UBS Group AG
$222.9K+199.4%
CITADEL ADVISORS LLC
$210.4KNew
VANGUARD FIDUCIARY TRUST CO
$193.1K+61.3%
STATE STREET CORP
$129.9K0.0%
FMR LLC
$127.3K0.0%
WILEY BROS.-AINTREE CAPITAL, LLC
$117.9K+3.4%
JONES FINANCIAL COMPANIES LLLP
$82.7K-52.1%
NORTHERN TRUST CORP
$79.4K+55.1%
HighTower Advisors, LLC
$57.8K0.0%
Quadrature Capital Ltd
$53.6KNew
Headlands Technologies LLC
$36.0KNew
StoneX Group Inc.
$29.2KNew
Beacon Pointe Advisors, LLC
$26.6K-0.2%
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$24.3KNew
Portfolio Strategies, Inc.
$23.7K+38.2%
Virtu Financial LLC
$23.0KNew
OSAIC HOLDINGS, INC.
$22.9K0.0%
TWO SIGMA SECURITIES, LLC
$15.2KNew
Diversify Advisory Services, LLC
$13.0KNew
See all 47 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q2 2026
EDGAR

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Debt/Equity

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/BTAI

Earnings Per Share

13fpro.ai/company/BTAI

Loading ratio trend…

BTAI key financials by period

Reported revenue, net income and operating margin by fiscal year, from BioXcel Therapeutics, Inc.'s annual filings on SEC EDGAR.

BioXcel Therapeutics, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$642.0K$-69.9M—
FY 2024$2.3M$-59.6M—
FY 2023$1.4M$-179.1M—
FY 2022$375.0K$-165.8M—
Source: BTAI filings on SEC EDGAR →

BTAI insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About BioXcel Therapeutics, Inc. (BTAI): stock profile, AI score and financials

Filed for bankruptcy: BioXcel Therapeutics, Inc. (BTAI) no longer trades and has left 13F Pro's AI-ranked universe. The bankruptcy filing was reported on August 28, 2026 (SEC 8-K 1.03). Its last closing price was on September 4, 2026. It has left the AI-ranked universe. The score and rank below are its final ones, from August 25, 2026. BioXcel Therapeutics, Inc. (BTAI) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro tracks BTAI using direct SEC EDGAR data and AI-powered research tools. Based on the latest XBRL financial filings (Q2 2026), BioXcel Therapeutics, Inc. reports quarterly revenue of $182.0K, net income of $-14.7M, free cash flow of $-6.1M. Top institutional holders of BTAI by reported 13-F value include MILLENNIUM MANAGEMENT, OAKTREE CAPITAL MANAGEMENT, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. BTAI trades on the Nasdaq exchange and files with the SEC under CIK 1720893. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BTAI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BioXcel Therapeutics, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1720893 →